Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullish

What exactly is the government’s cancer-drug trade-margin cap, and which part of the medicine supply chain does it regulate?

The government’s cancer-drug trade-margin cap is a policy to curb excessive mark-ups in the medicine distribution chain. It is intended to make cancer treatment more affordable while keeping medicines available. The article says the measure extends an earlier cap that applied only to select oncology drugs.

The regulated area is the trade margin added as medicines move through the distribution chain. In practical terms, the policy focuses on pricing between the medicine manufacturer, distributors, pharmacies, and the final sale. The article does not state the exact percentage limit or identify every covered product.

The policy matters for hospitals because pharmacies contribute 15-20% of overall revenue, according to Emkay. Jefferies also says consumables represent about 12-15% of a patient’s hospital bill. Lower permitted mark-ups could pressure some revenue and margins, although analysts expect the overall EBITDA effect to remain manageable.

How large a share of a hospital bill comes from consumables such as medicines, stents, implants, and other medical supplies?

Jefferies estimates that consumables account for around 12-15% of a patient’s hospital bill. This category includes medicines, stents, implants, and other medical supplies used during treatment. The figure shows that consumables matter, but they are not the entire hospital bill.

The share does not equal the hospitals’ profit from consumables. Jefferies says margins in this segment are relatively low because high-value products such as stents and implants have been subject to price caps since 2017. Emkay separately says pharmacies contribute 15-20% of overall hospital revenue and carry 20-25% margins.

These figures help explain why analysts expect a limited overall earnings impact from new restrictions. Consumables are meaningful, but hospitals earn revenue from several other services. Any pressure may also differ by patient type, because insured and public-scheme patients often use pre-negotiated package rates rather than headline prices.

Why did Apollo, Max Health, Fortis, and other hospital stocks rise even though the policy could reduce hospitals’ margins?

Hospital stocks rose because investors focused on the expected long-term recovery rather than only the immediate margin risk. Jefferies said near-term margins could be affected, but considered the impact transitory and recommended buying as regulatory uncertainty eased for now. The sector’s strong demand for quality tertiary-care beds also supported sentiment.

The market reaction was broad. Fortis Healthcare gained over 5%, Max Health more than 4%, Apollo Hospitals 4%, Manipal 3.5%, Medanta 3.1%, and Dr Agarwal’s 2% on the BSE. Investors also considered earlier experience with price controls, when hospitals adapted through procedure-price increases and cost rationalisation.

Valuations had already corrected. Jefferies said hospital stocks traded around 21x-25x FY28E EV/EBITDA, versus 25x-35x a year earlier. It preferred Fortis, Manipal, Apollo Hospitals, Max Healthcare, and Medanta, especially companies capable of high-teens EBITDA growth.

What could happen to hospitals’ revenue and EBITDA if they can no longer apply large mark-ups to cancer drugs and other consumables?

If hospitals cannot apply large mark-ups, prices charged for some cancer drugs and consumables could fall. That may reduce revenue earned from pharmacies and treatment-related supplies. Because EBITDA measures operating earnings before certain charges, lower gross margins on these items could temporarily reduce hospital EBITDA margins.

The impact may not be uniform. Jefferies estimates consumables at 12-15% of a patient’s bill and says margins in that segment are already relatively low. Emkay says pharmacies generate 15-20% of hospital revenue with 20-25% margins. It also expects caps to affect cash-paying patients more because insured patients often use negotiated package rates.

Both brokerages expect the overall effect to be manageable. Hospitals may respond through procedure-charge increases and cost controls, as they did after earlier price caps. Jefferies expects near-term earnings pressure, but says strong demand for quality tertiary-care beds supports the sector’s longer-term outlook.

How did hospitals respond when stent and knee-implant prices were cut by roughly 70% to 85% in 2017, and what does that history suggest about the current policy?

In 2017, cardiac stent and orthopaedic knee implant prices fell by roughly 70-85%. The sharp cuts threatened hospital margins because high-value consumables could no longer support the same mark-ups. The episode provides a direct historical comparison for investors assessing the current policy.

Hospitals responded over the following 12-15 months. They made staggered increases in procedure charges and introduced cost-rationalisation measures. These steps helped offset the lower prices of stents and implants without relying entirely on product mark-ups. Apollo Hospitals used a comparable approach in 2017-18.

Apollo restored its EBITDA margins to previous levels within a few quarters, according to Jefferies. The brokerage therefore expects a similar adjustment process to limit the current policy’s effect. It still expects near-term earnings pressure, while noting that regulatory developments historically weighed on hospital stocks for three to six months before recovery began.

Why might price caps affect cash-paying patients more than patients covered by insurance or public health schemes?

A price cap may affect cash-paying patients more because their bills can reflect hospitals’ published rates and medicine prices. If mark-ups on cancer drugs or consumables are reduced, the prices charged to these patients may change more directly. This can pressure the hospital’s revenue or margin on each affected item.

Patients covered by insurance or public health schemes generally use pre-negotiated package rates, according to Emkay. These packages are discounted from rack rates and tariffs. They are not usually calculated from headline maximum retail prices, so a change in those visible mark-ups may have a smaller immediate effect on the hospital’s realised revenue.

This distinction is one reason Emkay expects a limited earnings impact for its healthcare coverage universe. It does not eliminate regulatory risk, because hospitals still face pressure around affordability and pricing. However, the different billing arrangements could soften the effect on insured and publicly funded business.

What are hospital EBITDA margins, and why do investors use EBITDA to judge whether a hospital business can absorb regulatory changes?

EBITDA means earnings before interest, taxes, depreciation, and amortisation. An EBITDA margin is EBITDA expressed as a share of revenue. It shows how much operating profit remains before financing costs, taxes, and certain non-cash or long-term asset charges are considered.

For hospitals, the measure captures the earnings produced by beds, procedures, pharmacies, and other operations. If drug or consumable mark-ups fall, revenue or gross profit may decline, pulling down the EBITDA margin. Investors can compare this change across hospital companies without focusing first on differences in debt or asset depreciation.

The article uses EBITDA to assess whether regulatory pressure is temporary or structurally damaging. Jefferies expects near-term EBITDA effects but says they should be manageable. It also points to Apollo’s margin recovery after earlier price caps and favours companies capable of delivering sustainable EBITDA growth in the high teens.

Key Facts:

📌 The cap targets excessive mark-ups in the cancer-medicine distribution chain.

📌 It extends an earlier cap covering select oncology drugs.

📌 The article does not state the cap’s exact percentage.

📌 Consumables account for around 12-15% of a patient’s hospital bill.

📌 Pharmacies contribute 15-20% of overall hospital revenue.

📌 Stents and implants have faced price caps since 2017.

📌 Jefferies called the expected near-term margin impact transitory.